A cancer drug which reportedly helped keep the Lockerbie bomber alive for an extra two-and-a-half years may soon be made available on the NHS.
The Scottish Medicines Consortium (SMC) decides on Monday whether to approve abiraterone to treat people with prostate cancer.
Scotland is the only part of the UK where patients cannot get the medication which is designed to extend life and improve quality of life for those in the advanced stages of the disease.
Please enable cookies in your browser to display the rest of this article.